We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$9.59B
AUM Growth
+$1.11B
Cap. Flow
-$1.32B
Cap. Flow %
-13.72%
Top 10 Hldgs %
53.17%
Holding
94
New
11
Increased
13
Reduced
11
Closed
12

Top Buys

Rank Stock Value
1
GMAB icon
Genmab
GMAB
+$117M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$109M
3
BSX icon
Boston Scientific
BSX
+$71.4M
4
PBLS
Parabilis Medicines Inc
PBLS
+$52M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$36.3M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$141M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$97.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$80.4M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$79.8M
5
EHAB
Enhabit
EHAB
+$66.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.76%
2 Miscellaneous 16.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
51
Alnylam Pharmaceuticals
ALNY
$35.4B
$20.5M 0.21%
67,935
– –
DRUG
52
Bright Minds Biosciences
DRUG
$667M
$19.9M 0.21%
283,000
– –
ODTX
53
Odyssey Therapeutics
ODTX
$1.27B
$19.6M 0.2%
+1,046,139
New +$18.3M
STLN
54
Starling Oncology
STLN
$608M
$18.2M 0.19%
3,360,052
– –
KYTX icon
55
Kyverna Therapeutics
KYTX
$516M
$17.8M 0.19%
2,000,000
– –
ALMR
56
Alamar Biosciences
ALMR
$2.12B
$16.3M 0.17%
+600,000
New +$13.6M
CHE icon
57
Chemed
CHE
$6.85B
$14M 0.15%
+30,000
New +$12.6M
SGP
58
SpyGlass Pharma
SGP
$970M
$12.2M 0.13%
550,000
– –
ADAG
59
Adagene
ADAG
$248M
$11.2M 0.12%
+2,666,666
New +$10M
COAG
60
Hemab Therapeutics
COAG
$2.07B
$10.1M 0.11%
+275,000
New +$7.59M
MOBI
61
Mobia Medical
MOBI
$387M
$8.99M 0.09%
+670,752
New +$8.69M
EMBC icon
62
Embecta
EMBC
$322M
$8.26M 0.09%
2,534,961
– –
VCYT icon
63
Veracyte
VCYT
$3.59B
$5.93M 0.06%
101,000
-625,000
-86% -$26.2M
ANNX icon
64
Annexon
ANNX
$918M
$3.33M 0.03%
583,913
– –
ALEC icon
65
Alector
ALEC
$280M
$2.12M 0.02%
1,055,192
– –
NAMSW icon
66
NewAmsterdam Pharma Warrant
NAMSW
$66.4M
$1.98M 0.02%
92,787
– –
EW icon
67
Edwards Lifesciences
EW
$51.7B
$1.24M 0.01%
13,702
– –
MIRM icon
68
Mirum Pharmaceuticals
MIRM
$6.14B
$706K 0.01%
+6,027
New +$605K
HUM icon
69
Humana
HUM
$48.8B
$364K ﹤0.01%
917
– –
STLNW
70
Starling Oncology Warrant
STLNW
$51K ﹤0.01%
1,250,000
– –
PMVP icon
71
PMV Pharmaceuticals
PMVP
$66.3M
$11.8K ﹤0.01%
8,790
– –
SRZNW
72
DELISTED
Surrozen Inc Warrant
SRZNW
$2.75K ﹤0.01%
166,666
– –
CGEM icon
73
Cullinan Oncology
CGEM
$1.43B
– –
-386,169
Closed -$5.49M
CMPX icon
74
Compass Therapeutics
CMPX
$427M
– –
-3,606,000
Closed -$19.1M
CPRX
75
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-3,943,600
Closed -$97.6M
1 2
3
4

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q2 2026 Portfolio in Review

As of Q2 2026, Deerfield Management held 94 positions worth $9.59B, up 13% from $8.48B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deerfield Management withdrew a net $1.32B in Q2 2026, closing 12 positions and reducing 11 holdings. Its most notable exit was Catalyst Pharmaceutical, an estimated $97.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, Deerfield Management opened a new position in Mineralys Therapeutics worth $107M.

  • Deerfield Management's largest Q2 2026 buy was Mineralys Therapeutics: 3,958,000 shares worth $107M.
  • Deerfield Management added most to Genmab in Q2 2026, an estimated $117M increase.
  • Deerfield Management's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $141M.
  • Deerfield Management fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $97.6M.
  • Deerfield Management's ten largest holdings make up 53% of its $9.59B portfolio in Q2 2026.
  • Deerfield Management opened 11 new positions and closed 12 in Q2 2026.
  • Deerfield Management's portfolio value rose 13% quarter-over-quarter to $9.59B.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.